

JUL 26 2005

Chidicon Medical Center

INTERNATIONAL INSTITUTES OF ADVANCED RESEARCH & TRAINING

Prince Dr Philip C. Njemanze MD

CHAIRMAN

July 20th 2005

Examiner: D. L. Jones
Supervisor: Thurman PageNo 1 Uretha/MCC Road, P. O. Box 302,
Owerri, Imo State, Nigeria.
Tel: 083-231189
eFax (USA): 819-489-0415
email: philip.njemanze@chidicon.com**US Patent Application: 10/635,820****Art Unit: 1618**<http://geo.arc.nasa.gov/esg/health/twhew/njemanze.html>

Dear Madam,

Election of Option II

In reference to your communication dated 6/29/2005 received today in my office in Owerri, Nigeria. I want to elect for examination Page 2 paragraph 2, Option II Claims 9-13, drawn to a method and system for controlling infectious diseases as set forth in independent claim 9, classified in class 424, subclass 9.1+. Hydrophobic/hydrophilic active ingredients such as those in claims 10, 11, 12, 13 are selected. Targeted tissue cells as set forth in claim 9 (h) and 12. The control of infectious diseases as set forth in claims 10-13. Tissue specific peptide, natural protein channels and tissue specific membrane proteins as implied in claim 12. Specific drug of interest as set forth in claims 10, 11, and 13.

I thank you in anticipation.

Yours truly,



Dr Philip C. Njemanze

BEST AVAILABLE COPY